<DOC>
	<DOCNO>NCT02536911</DOCNO>
	<brief_summary>Primary Objective : To study effect mild moderate hepatic impairment pharmacokinetics ( PK ) eliglustat . Secondary Objective : To assess tolerability eliglustat tartrate give single dose subject mild moderate hepatic impairment comparison match subject normal hepatic function .</brief_summary>
	<brief_title>A Study Effects Hepatic Impairment Pharmacokinetics Tolerability Eliglustat Tartrate</brief_title>
	<detailed_description>The total study duration screen period approximately 31 day .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>Inclusion criterion : For subject hepatic impairment : Male female subject , 18 79 year age , inclusive . Body weight 50.0 125.0 kg , inclusive male , 40.0 110.0 kg , inclusive female , body mass index ( BMI ) 18.0 37 kg/m^2 , inclusive . Stable chronic liver disease assess medical history , physical examination , laboratory value . For moderate hepatic impairment cohort : ChildPugh total score range 7 9 , inclusive . For mild hepatic impairment cohort : ChildPugh total score range 5 6 , inclusive . For matched subject : Male female subject , 18 79 year age , inclusive . Body weight within 15 % body weight subject hepatic impairment BMI 18.0 37 kg/m^2 , inclusive . Matched cytochrome P450 ( CYP ) 2D6 predict phenotype base genotype . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Exclusion criterion : For subject hepatic impairment : Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Hepatocarcinoma . Acute hepatitis . Hepatic encephalopathy grade 2 , 3 , 4 . Presence history drug hypersensitivity , allergic disease , include active seasonal rhinitis , diagnose treated physician . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) within 2 year inclusion . If female , pregnancy ( define positive betahuman chorionic gonadotropin [ β HCG ] blood test ) , breastfeed . Pgp inhibitor and/or inducer , CYP2D6 and/or CYP3A inhibitor and/or inducer . Positive result follow test : antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 antiHIV2 Ab ) . Preexisting cardiac disease ( current congestive heart failure , recent acute myocardial infarction , bradycardia , heart block , ventricular arrhythmia ) , long QT syndrome , use Class IA ( eg , quinidine , procainamide ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medication . Any subject CYP2D6 indeterminate ultrarapid metabolizer ( URM ) phenotype . For matched subject : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Presence history drug hypersensitivity , allergic disease diagnose treated physician . If female , pregnancy ( define positive βHCG blood test ) , breastfeed . For subject 50 year age younger : medication ( include St John 's Wort ) within 14 day inclusion , within 5 time elimination halflife pharmacodynamic halflife medication , whichever long , exception hormonal contraception menopausal hormone replacement therapy , vaccination within last 28 day , biologics ( antibody derivative ) give within 4 month inclusion . For subject old 50 year age : significant change chronic treatment medication within 14 day inclusion . Pgp inhibitor and/or inducer , CYP2D6 and/or CYP3A inhibitor and/or inducer . Positive result follow test : hepatitis B surface antigen ( HBs Ag ) , antihepatitis C virus ( antiHCV ) antibody , antiHIV1 antiHIV2 Ab . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) within 2 year inclusion . Preexisting cardiac disease ( current congestive heart failure , recent acute myocardial infarction , bradycardia , heart block , ventricular arrhythmia ) , long QT syndrome , use Class IA ( eg , quinidine , procainamide ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>